<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1688-0420</journal-id>
<journal-title><![CDATA[Revista Uruguaya de Cardiología]]></journal-title>
<abbrev-journal-title><![CDATA[Rev.Urug.Cardiol.]]></abbrev-journal-title>
<issn>1688-0420</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Uruguaya de Cardiología]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1688-04202019000200071</article-id>
<article-id pub-id-type="doi">10.29277/cardio.34.2.7</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Casuística de pacientes asistidos en una policlínica de hipertensión arterial]]></article-title>
<article-title xml:lang="en"><![CDATA[Casuistry of patients attended in a polyclinic of arterial hypertension]]></article-title>
<article-title xml:lang="pt"><![CDATA[Casuística de pacientes atendidos na policlínica de hipertensão arterial]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Toledo]]></surname>
<given-names><![CDATA[María Victoria]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Spósito]]></surname>
<given-names><![CDATA[Paola]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Llorens]]></surname>
<given-names><![CDATA[Mario]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad de la República Facultad de Medicina Hospital Maciel]]></institution>
<addr-line><![CDATA[Montevideo ]]></addr-line>
<country>Uruguay</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>08</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>08</month>
<year>2019</year>
</pub-date>
<volume>34</volume>
<numero>2</numero>
<fpage>71</fpage>
<lpage>89</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_arttext&amp;pid=S1688-04202019000200071&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_abstract&amp;pid=S1688-04202019000200071&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_pdf&amp;pid=S1688-04202019000200071&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen:  Introducción:  la hipertensión arterial (HTA) es uno de los factores de riesgo cardiovascular más prevalentes en el mundo. La detección temprana, el tratamiento apropiado y su control determinan importantes beneficios en materia de salud y economía. Dada la alta incidencia de consultas por complicaciones vinculadas a esta enfermedad, se crea en el año 2014 la policlínica de HTA en el Hospital Maciel, realizándose en ella tratamiento integral de pacientes hipertensos, fundamentalmente de aquellos de difícil control.  Objetivo:  caracterizar la población de hipertensos que asisten a esta policlínica, así como mostrar los resultados de su implementación respecto al control de las cifras tensionales.  Material y método:  estudio descriptivo, longitudinal, retrospectivo y prospectivo entre los años 2015 y 2017 que incluyó a los pacientes que se asisten en dicha policlínica, excluyendo a embarazadas, menores de 18 años, pacientes que no se controlaron en el último año y fallecidos.  Resultados:  se analizó un total de 122 pacientes, media de edad 59,8 años, predominio sexo femenino (1,8:1). Factores de riesgo cardiovascular asociados: sobrepeso/obesidad (88%), dislipemia (65%), tabaquismo (39%) y diabetes (29%). Prevalencia de daño de órgano blanco en el momento de ser derivados, 62%. El 98% recibe tratamiento farmacológico: 71% terapia combinada. Predomina la HTA grado III (68,9%).  Conclusión:  la población se caracteriza por una elevada incidencia de sobrepeso/obesidad, HTA grado III, y alta prevalencia de daño de órgano blanco en el momento de la consulta, lo cual conduce a pensar que los pacientes se derivan tardíamente. En el subgrupo de hipertensos grado III se logró un adecuado control promedio de cifras tensionales en el seguimiento anual.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Summary:  Introduction:  high blood pressure is one of the most prevalent cardiovascular risk factors in the world. Early detection, appropriate treatment and control determine important health and economic benefits. Given the high incidence of consultations due to complications of this disease, in 2014 the hypertension polyclinic was created in the Maciel Hospital, in which evaluation and treatment of the hypertensive patient were carried out in an integral way, fundamentally for those with difficult control.  Objective:  to characterize the population of hypertensive patients attending this polyclinic, as well as to show the results of its implementation regarding the figures control.  Materials and methods:  descriptive, longitudinal, retro and prospective study between 2015-2017 that includes patients who are attended by polyclinic, excludes pregnant women, young persons under 18 years old, those who were not controlled in the last year and deceased.  Results:  122 patients were analysed, average age 59,8 years old, female sex 1.8:1. Associated cardiovascular risk factors: overweight/obesity (88%), dyslipidemia (65%), smoking (39%) and diabetes (29%). Prevalence of white organ damage 62% at the time of referral. 98% receive pharmacological treatment: 71% combined therapy. Hypertension grade III predominates (68,9%). Conclusion: the population is characterized by a high incidence of overweight/obesity, hypertension grade III as well as high prevalence of white organ damage at the time of consultation, which leads to think that the patients are derived late. In the subgroup of hypertensives grade III adequate average control of blood pressure figures was achieved in the annual follow-up.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Resumo:  Introdução:  a hipertensão arterial é um dos fatores de risco cardiovascular mais prevalentes no mundo. A detecção precoce, o tratamento e o controle apropriados determinam importantes benefícios econômicos e para a saúde. Dada a alta incidência de consultas relacionadas a complicações desta doença, foi criado em 2014 a policlínica de hipertensão em Hospital Maciel, realizando avaliação e tratamento de pacientes hipertensos de forma holística, principalmente daqueles de difícil controle.  Objetivo:  caracterizar a população de hipertensos atendidos nesta policlínica, bem como mostrar os resultados de sua implementação no controle de figuras.  Materiais e métodos:  estudo descritivo, longitudinal, retro e prospectivo, entre os anos de 2015 e 2017, que incluiu os pacientes que compareceram à policlínica, excluindo gestantes, menores de 18 anos, pacientes que não foram controlados no último ano e falecidos.  Resultados:  foram analisados 122 pacientes, idade média de 59,8 anos, sexo feminino 1,8: 1. Fatores de risco cardiovascular associados: sobrepeso/obesidade (88%), dislipidemia (65%), tabagismo (39%) e diabetes (29%). Prevalência de lesão de órgão branco 62% no momento do encaminhamento. 98% recebem tratamento farmacológico: 71% terapia combinada. Hipertensão grau III predomina (68,9%).  Conclusão:  a população é caracterizada por uma alta incidência de sobrepeso / obesidade, hipertensão grau III, bem como a alta prevalência de lesão de órgão branco no momento da consulta, o que leva a pensar que os pacientes são derivados tardiamente. No subgrupo de hipertensos grau III, o controle médio adequado dos valores da pressão arterial foi alcançado no seguimento anual.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Hipertensión]]></kwd>
<kwd lng="es"><![CDATA[Factores de riesgo]]></kwd>
<kwd lng="es"><![CDATA[Patrones de variabilidad]]></kwd>
<kwd lng="en"><![CDATA[Hypertension]]></kwd>
<kwd lng="en"><![CDATA[Risk factors]]></kwd>
<kwd lng="en"><![CDATA[Patterns of variability]]></kwd>
<kwd lng="pt"><![CDATA[Hipertensão]]></kwd>
<kwd lng="pt"><![CDATA[Factores de risco]]></kwd>
<kwd lng="pt"><![CDATA[Padrões de variabilidade]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="book">
<collab>World Health Organization</collab>
<source><![CDATA[A global brief on hypertension: silent killer, global public health crisis (Internet)]]></source>
<year>2013</year>
<publisher-loc><![CDATA[Geneva ]]></publisher-loc>
<publisher-name><![CDATA[WHO]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="book">
<collab>Organización Mundial de la Salud</collab>
<source><![CDATA[Informe sobre la situación mundial de las enfermedades no transmisibles 2010. Resumen de orientación (Internet)]]></source>
<year>2011</year>
<publisher-loc><![CDATA[Ginebra ]]></publisher-loc>
<publisher-name><![CDATA[OMS]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sandoya]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Torres]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Rivedieu]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Machado]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Nuñez]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Situación de la hipertensión arterial a nivel público y privado]]></article-title>
<source><![CDATA[Rev Urug Cardiol]]></source>
<year>2016</year>
<volume>31</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>219-27</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Williams B]]></surname>
<given-names><![CDATA[Azizi M]]></given-names>
</name>
<name>
<surname><![CDATA[Burnier]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[2018 ESC/ESH guidelines for the management of arterial hypertension.]]></article-title>
<source><![CDATA[Eur Heart J.]]></source>
<year>2018</year>
<volume>39</volume>
<page-range>3021-104</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gorostidi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Segura]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hipertensión arterial nocturna]]></article-title>
<collab>de la Sierra A</collab>
<source><![CDATA[Hipertens Riesgo Vasc]]></source>
<year>2010</year>
<volume>27</volume>
<numero>^s1</numero>
<issue>^s1</issue>
<supplement>1</supplement>
<page-range>S26-33</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nguyen]]></surname>
<given-names><![CDATA[NT]]></given-names>
</name>
<name>
<surname><![CDATA[Magno]]></surname>
<given-names><![CDATA[CP]]></given-names>
</name>
<name>
<surname><![CDATA[Lane]]></surname>
<given-names><![CDATA[KT]]></given-names>
</name>
<name>
<surname><![CDATA[Hinojosa]]></surname>
<given-names><![CDATA[MW]]></given-names>
</name>
<name>
<surname><![CDATA[Lane]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Association of hypertension, diabetes, dyslipidemia, and metabolic syndrome with obesity findings from the National Health and Nutrition Examination Survey, 1999 to 2004]]></article-title>
<source><![CDATA[J Am Coll Surg]]></source>
<year>2008</year>
<volume>207</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>928-34</page-range></nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="">
<source><![CDATA[]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Garrido]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Chacón]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Sandoval]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Muñoz]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[López]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Oyarzún]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Control del hipertenso, un desafío no resuelto Avances logrados en Chile mediante el programa de salud cardiovascular]]></article-title>
<source><![CDATA[Rev Chil Cardiol]]></source>
<year>2013</year>
<volume>32</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>85-96</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schargrodsky]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Hernández-Hernández]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Champagne]]></surname>
<given-names><![CDATA[BM]]></given-names>
</name>
<name>
<surname><![CDATA[Silva]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Vinueza]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Silva Ayçaquer]]></surname>
<given-names><![CDATA[LC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[CARMELA assessment of the CV risk in seven Latin American cities]]></article-title>
<source><![CDATA[Am J Med]]></source>
<year>2008</year>
<volume>121</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>58-65</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<collab>De la Sierra A</collab>
<article-title xml:lang=""><![CDATA[La monitorización ambulatoria de la presión arterial es un instrumento aconsejable para todos los pacientes]]></article-title>
<source><![CDATA[Hipertens Riesgo Vasc]]></source>
<year>2017</year>
<volume>34</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>45-99</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Doménech Feria-Carot]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Sobrino Martínez]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hipertensión nocturna]]></article-title>
<source><![CDATA[Hipertens Riesgo Vasc]]></source>
<year>2011</year>
<volume>28</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>143-8</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Turnbull]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effects of different blood-pressure-lowering regimens on major cardiovascular events results of prospectively-designed overviews of randomised trials]]></article-title>
<collab>Blood Pressure Lowering Treatment Trialists Collaboration</collab>
<source><![CDATA[Lancet]]></source>
<year>2003</year>
<volume>362</volume>
<numero>9395</numero>
<issue>9395</issue>
<page-range>1527-35</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fasce]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Campos]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Ibáñez]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Flores]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Zárate]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Román]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Trends in prevalence, awareness, treatment and control of hypertension in urban communities in Chile]]></article-title>
<source><![CDATA[J Hypertens]]></source>
<year>2007</year>
<volume>25</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1807-11</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
